Recent events
Recent events tied to this brand in public sources.
Back to profile56 entries · Page 1 of 3
2026
Lilly agrees to acquire Calytrix Bio
Calytrix Bio announced a definitive agreement for Eli Lilly and Company to acquire it. Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment and subsequent payments tied to clinical and regulatory milestones.
2026
Richter and Lilly enter licensing agreement for women’s health and cardiometabolic medicines
Gedeon Richter entered into a licensing agreement with Eli Lilly and Company under which Richter will grant Lilly exclusive worldwide rights to develop, manufacture and commercialize jointly developed medicines for women’s health conditions and cardiometabolic diseases. A separate supply agreement covers the active pharmaceutical ingredient Estetrol (E4).
2026
Lilly raises 2026 revenue outlook
Eli Lilly and Company raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. It also raised its non-GAAP performance-margin outlook and lowered its non-GAAP earnings-per-share forecast.
2026
Jitai Technology and Eli Lilly form an AI-LNP platform partnership
Jitai Technology and Eli Lilly entered a strategic collaboration in which Jitai will use its AiLNP platform to develop LNP delivery technology, while Lilly will contribute resources in drug discovery, development, and commercialization.
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
2026
Caspian Therapeutics raises $50 million in financing led by BVF Partners
Caspian Therapeutics has raised $50 million in financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura and other investors. The proceeds are expected to fund IND-enabling work, an initial clinical proof-of-concept program and advancement of a second menin inhibitor candidate.
2026
Ascidian Therapeutics and Eli Lilly announce kidney disease research collaboration
Ascidian Therapeutics and Eli Lilly announced a global research collaboration and licensing agreement to discover and develop therapies for undisclosed monogenic kidney diseases. Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for the targets.
2026
WHO Foundation and Lilly announce obesity-care collaboration
The WHO Foundation announced a collaboration with Eli Lilly and Company, which is committing $1.68 million through 2029 to support efforts to assess and strengthen health systems for obesity prevention and care.
2025
Indiana sues Eli Lilly over alleged insulin price-fixing
Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.
2024
Zuellig Pharma completes acquisition of Cialis and Alimta brands
Zuellig Pharma concluded the acquisition of the Cialis and Alimta brands from Eli Lilly through its wholly owned subsidiary Zanovex. The transaction covers eight ASEAN markets, and Zanovex will hold the trademarks and marketing authorisations for both brands.
2024
UpDoc announces strategic funding round
UpDoc announced a strategic funding round led by Polaris Partners, with participation from Oxeon Partners, Eli Lilly & Company, and Mayo Clinic.
2024
Eli Lilly announces LillyDirect
Eli Lilly and Company announced LillyDirect, a U.S. digital healthcare experience for patients living with obesity, migraine and diabetes. It offers disease-management resources, access to independent healthcare providers and direct home delivery of select Lilly medicines.
2023
PDL BioPharma sues Eli Lilly over donanemab royalties
PDL BioPharma filed suit against Eli Lilly on December 21, 2023, alleging anticipatory breach of contract and claiming that Lilly owes royalties for technology PDL says was used in donanemab. Lilly called the lawsuit baseless and denied using PDL technology in developing the drug.
2023
FDA approves Jaypirca for CLL/SLL
The FDA granted accelerated approval to Jaypirca (pirtobrutinib) for adults with CLL or SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
2023
Arizona files insulin pricing lawsuit
Arizona Attorney General Kris Mayes filed a lawsuit on November 27 against pharmaceutical manufacturers and pharmacy benefit managers, alleging they inflated prices for insulin and other diabetes drugs in violation of the Arizona Consumer Fraud Act. The named defendants include CVS Caremark, Express Scripts, OptumRx, Novo Nordisk, Sanofi-Aventis U.S. LLC, and Eli Lilly and Company.
2023
Washington County sues insulin makers over pricing
Washington County filed a lawsuit against insulin makers and healthcare companies, alleging that they unjustifiably raised diabetes medication prices. The county alleges Eli Lilly artificially inflated list prices; Eli Lilly called the allegations baseless and said it would defend against them.
2023
FDA approves Zepbound for chronic weight management
The US Food and Drug Administration approved Eli Lilly's tirzepatide, branded as Zepbound, for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
2023
FDA approves Lilly’s Omvoh for ulcerative colitis
The U.S. Food and Drug Administration approved Omvoh, Eli Lilly’s treatment for moderately to severely active ulcerative colitis in adults.
2023
Lilly completes acquisition of Versanis Bio
Eli Lilly and Company completed its acquisition of clinical-stage biopharmaceutical firm Versanis Bio. The acquisition adds Versanis’ lead asset, bimagrumab, to Lilly’s portfolio.
2023
Mission BioCapital launches 2023 Platinum Program with Eli Lilly as founding sponsor
Mission BioCapital announced the launch of its 2023 Platinum Program in collaboration with Eli Lilly and Company as founding sponsor. The program will offer selected life sciences startups incubator lab space, seed funding and mentorship.